110 related articles for article (PubMed ID: 29658363)
21. Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo.
Kluza E; Jacobs I; Hectors SJ; Mayo KH; Griffioen AW; Strijkers GJ; Nicolay K
J Control Release; 2012 Mar; 158(2):207-14. PubMed ID: 22079810
[TBL] [Abstract][Full Text] [Related]
22. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
23. Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression.
Li W; Liu Z; Li C; Li N; Fang L; Chang J; Tan J
J Cancer Res Clin Oncol; 2016 Mar; 142(3):619-32. PubMed ID: 26573511
[TBL] [Abstract][Full Text] [Related]
24. 67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy: stability, therapeutic efficacy, and safety studies in mice.
Jin ZH; Furukawa T; Ohya T; Degardin M; Sugyo A; Tsuji AB; Fujibayashi Y; Zhang MR; Higashi T; Boturyn D; Dumy P; Saga T
Nucl Med Commun; 2017 Apr; 38(4):347-355. PubMed ID: 28291159
[TBL] [Abstract][Full Text] [Related]
25. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
[TBL] [Abstract][Full Text] [Related]
26. Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer.
Wang H; Cai Z; Yang F; Luo J; Satoh M; Arai Y; Li D
Urology; 2014 Feb; 83(2):508.e13-9. PubMed ID: 24315309
[TBL] [Abstract][Full Text] [Related]
27. Targeted thermal therapy with genetically engineered magnetite magnetosomes@RGD: Photothermia is far more efficient than magnetic hyperthermia.
Plan Sangnier A; Preveral S; Curcio A; K A Silva A; Lefèvre CT; Pignol D; Lalatonne Y; Wilhelm C
J Control Release; 2018 Jun; 279():271-281. PubMed ID: 29684497
[TBL] [Abstract][Full Text] [Related]
28. Fabrication of genistein-loaded biodegradable TPGS-b-PCL nanoparticles for improved therapeutic effects in cervical cancer cells.
Zhang H; Liu G; Zeng X; Wu Y; Yang C; Mei L; Wang Z; Huang L
Int J Nanomedicine; 2015; 10():2461-73. PubMed ID: 25848264
[TBL] [Abstract][Full Text] [Related]
29. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy.
Rengaswamy V; Zimmer D; Süss R; Rössler J
J Control Release; 2016 Aug; 235():319-327. PubMed ID: 27261335
[TBL] [Abstract][Full Text] [Related]
30. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of multi-target and single-target liposomal drugs for the treatment of gastric cancer.
Chen CH; Liu DZ; Fang HW; Liang HJ; Yang TS; Lin SY
Biosci Biotechnol Biochem; 2008 Jun; 72(6):1586-94. PubMed ID: 18540096
[TBL] [Abstract][Full Text] [Related]
32. Dual function of RGD-modified VEGI-192 for breast cancer treatment.
Wu J; Jiang Y; Yang W; He Z; Meng S; Zhang Q; Lin M; Zhang H; Li W; Yang Y; Jia Y; Qian L; Lu D; Cai W; Luo G; Wang Y; Zhu X; Li M
Bioconjug Chem; 2012 Apr; 23(4):796-804. PubMed ID: 22455451
[TBL] [Abstract][Full Text] [Related]
33. An RGD-modified hollow silica@Au core/shell nanoplatform for tumor combination therapy.
Li X; Xing L; Hu Y; Xiong Z; Wang R; Xu X; Du L; Shen M; Shi X
Acta Biomater; 2017 Oct; 62():273-283. PubMed ID: 28823719
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneous dimer peptide-conjugated polylysine dendrimer-Fe
Shen JM; Li XX; Fan LL; Zhou X; Han JM; Jia MK; Wu LF; Zhang XX; Chen J
Int J Nanomedicine; 2017; 12():1183-1200. PubMed ID: 28243083
[TBL] [Abstract][Full Text] [Related]
35. 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.
Jiang L; Miao Z; Liu H; Ren G; Bao A; Cutler CS; Shi H; Cheng Z
Nucl Med Commun; 2013 Sep; 34(9):909-14. PubMed ID: 23708872
[TBL] [Abstract][Full Text] [Related]
36. Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I.
Tang J; Wang X; Xu Y; Shi Y; Liu Z; Yang Y
Technol Cancer Res Treat; 2015 Feb; 14(1):61-9. PubMed ID: 24354753
[TBL] [Abstract][Full Text] [Related]
37. Delivery of vincristine sulfate-conjugated gold nanoparticles using liposomes: a light-responsive nanocarrier with enhanced antitumor efficiency.
Liu Y; He M; Niu M; Zhao Y; Zhu Y; Li Z; Feng N
Int J Nanomedicine; 2015; 10():3081-95. PubMed ID: 25960649
[TBL] [Abstract][Full Text] [Related]
38. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system.
Gupta AS; Huang G; Lestini BJ; Sagnella S; Kottke-Marchant K; Marchant RE
Thromb Haemost; 2005 Jan; 93(1):106-14. PubMed ID: 15630499
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy.
van Hagen PM; Breeman WA; Bernard HF; Schaar M; Mooij CM; Srinivasan A; Schmidt MA; Krenning EP; de Jong M
Int J Cancer; 2000 Aug; 90(4):186-98. PubMed ID: 10993959
[TBL] [Abstract][Full Text] [Related]
40. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
